Leukemia News

Flumatinib Shows Promise in Chronic-Phase Chronic Myeloid Leukemia (September 3, 2019)

Flumatinib may be more effective than Gleevec (imatinib) for initial treatment of chronic phase-chronic myeloid leukemia (CML-CP) according to study results presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. Chronic... Continue Reading

Vaccine for Acute Myeloid Leukemia? (August 14, 2019)

A personalized cancer vaccine markedly improved outcomes for patients suffering from acute myeloid leukemia (AML), a potentially lethal blood cancer, in a clinical trial led by investigators at Beth Israel Deaconess Medical Center (BIDMC). The product... Continue Reading

Calquence Improves Survival in Relapsed Chronic Lymphocytic Leukemia (May 20, 2019)

An interim analyses of the phase 3 “ASCEND” clinical trial evaluating single-agent Calquence (acalabrutinib) compared to Rituxan (rituximab) plus idelasib or bendamustine in recurrent chronic lymphocytic leukemia (CLL) is closed early due to favorable... Continue Reading

FDA approves ivosidenib as first-line treatment for AML with IDH1 mutation (May 7, 2019)

On May 2, 2019, the Food and Drug Administration approved ivosidenib (TIBSOVO, Agios Pharmaceuticals, Inc.) for newly-diagnosed acute myeloid leukemia (AML) with a susceptible IDH1 mutation, as detected by an FDA-approved test, in patients who are at... Continue Reading

Non-Chemotherapy Combo Approved for Treatment-Naïve CLL/SLL Patients (March 11, 2019)

The U.S. Food and Drug Administration (FDA) has approved IMBRUVICA® (ibrutinib) in combination with Gazyva (obinutuzumab) for treatments of patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). 1 The FDA approval was based... Continue Reading

Gilteritinib Approved for Advanced Acute Myeloid Leukemia (AML) with a FLT3 Mutation (November 29, 2018)

The U.S. Food and Drug Administration approved Xospata (gilteritinib) for treatment of adult patients who have recurrent or refractory acute myeloid leukemia (AML) with a FLT3 mutation. About Xospata Xospata has demonstrated inhibitory activity against... Continue Reading

FDA Approves Venclexta Combination for AML in Adults (November 26, 2018)

The Food and Drug Administration granted accelerated approval to Venclexta (venetoclax) in combination with azacitidine or decitabine or low-dose cytarabine for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adults who are age 75 years... Continue Reading

duvelisib (COPIKTRA, Verastem, Inc.) for adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) (September 25, 2018)

The Food and Drug Administration granted regular approval to duvelisib (COPIKTRA, Verastem, Inc.) for adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) after at least two prior therapies. In... Continue Reading

Tibsovo Approved for Treatment of Relapsed/Refractory Acute Myeloid Leukemia and an IGH1 Mutation (July 23, 2018)

Tibsovo® (ivosidenib) has been granted approval from the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (R/R AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation... Continue Reading

FDA Approves Venetoclax for Chronic and Small Lymphocytic Leukemia/Lymphoma With or Without 17 p Deletion, (June 25, 2018)

The Food and Drug Administration granted regular approval to Venclexta (venetoclax) for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), with or without 17p deletion, who have received at least one prior therapy. Approval... Continue Reading

Latest Leukemia News By Stage


Acute Lymphoblastic Leukemia

FDA Approves Mylotarg for Treatment of Acute Myeloid Leukemia (September 5, 2017)

The U.S. Food and Drug Administration today approved Mylotarg (gemtuzumab ozogamicin) for the treatment of adults with newly diagnosed acute myeloid leukemia whose tumors express the CD33 antigen (CD33-positive AML). The FDA also approved Mylotarg for... Continue Reading

FDA Approves First Gene Therapy (September 1, 2017)

CAR T-cell therapy approved to treat certain children and young adults with B-cell acute lymphoblastic leukemia The U.S. Food and Drug Administration issued a historic action today making the first gene therapy available in the United States, ushering... Continue Reading

FDA Approves First Gene Therapy (September 1, 2017)

CAR T-cell therapy approved to treat certain children and young adults with B-cell acute lymphoblastic leukemia The U.S. Food and Drug Administration issued a historic action today making the first gene therapy available in the United States, ushering... Continue Reading

The US Food and Drug Administration has approved Besponsa for the Treatment of Refractory B-cell Precursor Acute Lymphoblastic Leukemia (August 22, 2017)

Besponsa (Inotuzumab ozogamicin) is a targeted therapy designed to bind to B-cell acute lymphoblastic leukemia (ALL) cancer cells that express the CD22 antigen. Acute lymphoblastic leukemia comprises approximately 25% of cancer diagnoses among children... Continue Reading

FDA Grants Iclusig® Expanded Approval for CML (December 14, 2016)

The United States Food and Drug Administration (FDA) has granted Iclusig® (ponatinib) approval to treat all phases of chronic myeloid leukemia (CML) in adults, as well as Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ALL) who are... Continue Reading

More Acute Lymphoblastic Leukemia

Acute Myeloid Leukemia

Vaccine for Acute Myeloid Leukemia? (August 14, 2019)

A personalized cancer vaccine markedly improved outcomes for patients suffering from acute myeloid leukemia (AML), a potentially lethal blood cancer, in a clinical trial led by investigators at Beth Israel Deaconess Medical Center (BIDMC). The product... Continue Reading

Gilteritinib Approved for Advanced Acute Myeloid Leukemia (AML) with a FLT3 Mutation (November 29, 2018)

The U.S. Food and Drug Administration approved Xospata (gilteritinib) for treatment of adult patients who have recurrent or refractory acute myeloid leukemia (AML) with a FLT3 mutation. About Xospata Xospata has demonstrated inhibitory activity against... Continue Reading

FDA Approves Venclexta Combination for AML in Adults (November 26, 2018)

The Food and Drug Administration granted accelerated approval to Venclexta (venetoclax) in combination with azacitidine or decitabine or low-dose cytarabine for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adults who are age 75 years... Continue Reading

Tibsovo Approved for Treatment of Relapsed/Refractory Acute Myeloid Leukemia and an IGH1 Mutation (July 23, 2018)

Tibsovo® (ivosidenib) has been granted approval from the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (R/R AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation... Continue Reading

U.S. FDA Approves Trisenox® Injection for First Line Treatment of Acute Promyelocytic Leukemia (January 31, 2018)

CancerConnect News: the U.S. Food and Drug Administration (FDA) has approved the use of Trisenox® (arsenic trioxide) injection in combination with tretinoin for the treatment of adults with newly-diagnosed low-risk acute promyelocytic leukemia (APL)... Continue Reading

More Acute Myeloid Leukemia

Acute Promyelocytic Leukemia

Many Patients with “Chemo Brain” Recover within Five Years (May 23, 2011)

A study of “chemo brain”—the foggy thinking and forgetfulness that patients may experience after chemotherapy—suggests that the condition improves substantially over time for a majority of patients. For some patients, however, symptoms may persist... Continue Reading

More Acute Promyelocytic Leukemia

Adult Acute Lymphoblastic Leukemia

FDA Places Hold on a Trial Evaluating Genetically Engineered Immune Cells for Cancer Treatment (July 18, 2016)

The United States Food and Drug Administration (FDA) has placed a hold on a clinical trial, referred to as the ROCKET trial, due to side effects of the treatment that may be associated with 3 patient deaths. Chimeric antigen receptor (CAR) technology... Continue Reading

Amgen’s BiTE® Immunotherapy Blinatumomab Receives FDA Priority Review Designation In Acute Lymphoblastic Leukemia (October 10, 2014)

THOUSAND OAKS, Calif., Oct. 9, 2014 /PRNewswire/ – Amgen (NASDAQ: AMGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for the investigational bispecific T cell... Continue Reading

Many Patients with “Chemo Brain” Recover within Five Years (May 23, 2011)

A study of “chemo brain”—the foggy thinking and forgetfulness that patients may experience after chemotherapy—suggests that the condition improves substantially over time for a majority of patients. For some patients, however, symptoms may persist... Continue Reading

More Adult Acute Lymphoblastic Leukemia

Childhood Acute Lymphoblastic Leukemia

Rituxan Improves Survival in Young Adults with Acute Lymphoblastic Leukemia (September 26, 2016)

Acccording to results recently published in the New England Journal of Medicine, young adults with CD20-positive, Philadelphia chromosome  (PH)-negative acute lymphoblastic leukemia (ALL), experience survival benefits with the addition of Rituxan® (rituximab)... Continue Reading

One Subset of Childhood Acute Lymphoblastic Leukemia is Best Treated with Chemotherapy (April 20, 2012)

A subset of young patients with acute lymphoblastic leukemia (ALL) who fail to achieve remission after the initial weeks of intense chemotherapy known as induction therapy appear to have better outcomes with additional chemotherapy rather than bone marrow... Continue Reading

Many Patients with “Chemo Brain” Recover within Five Years (May 23, 2011)

A study of “chemo brain”—the foggy thinking and forgetfulness that patients may experience after chemotherapy—suggests that the condition improves substantially over time for a majority of patients. For some patients, however, symptoms may persist... Continue Reading

More Childhood Acute Lymphoblastic Leukemia

Chronic Lymphoblastic Leukemia

Calquence Improves Survival in Relapsed Chronic Lymphocytic Leukemia (May 20, 2019)

An interim analyses of the phase 3 “ASCEND” clinical trial evaluating single-agent Calquence (acalabrutinib) compared to Rituxan (rituximab) plus idelasib or bendamustine in recurrent chronic lymphocytic leukemia (CLL) is closed early due to favorable... Continue Reading

Personalized Cell Therapy Combined with Imbruvica Achieves Complete Remission in High Percentage of Chronic Lymphocytic Leukemia Patients (June 5, 2017)

Combining the kinase inhibitor Imbruvica (ibrutinib) with an investigational personalized cellular therapy known as CTL119 can lead to complete remission in patients with high-risk chronic lymphocytic leukemia (CLL), according to new research from the Perelman... Continue Reading

Imbruvica® Effective in Newly Diagnosed and Recurrent Chronic Lymphocytic Leukemia (July 11, 2016)

Imbruvica (ibrutinib) produces long-lasting anti-cancer responses among patients with newly diagnosed chronic lymphocytic leukemia (CLL), as well as those who have received prior therapies. These results were recently presented at the 2016 annual meeting... Continue Reading

Arzerra® Approved as Maintenance Therapy for Advanced CLL (February 29, 2016)

The United States Food and Drug Administration (FDA) has approved Arzerra® (ofatumumab) as maintenance therapy for the treatment of advanced chronic lymphocytic leukemia (CLL). This product is already approved to treat patients with CLL who have not... Continue Reading

FDA Approves New Treatment Options for Low Grade Lymphomas and Chronic Lymphocytic Leukemia (August 25, 2014)

Gilead Sciences has confirmed FDA approval of Zydelig (idelalisib) for relapsed chronic lymphocytic leukemia (CLL), follicular lymphoma (FL) and small lymphocytic lymphoma (SLL). Non-Hodgkin’s lymphoma (NHL) is a form of cancer that begins in the cells... Continue Reading

More Chronic Lymphoblastic Leukemia

Chronic Lymphocytic Leukemia

duvelisib (COPIKTRA, Verastem, Inc.) for adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) (September 25, 2018)

The Food and Drug Administration granted regular approval to duvelisib (COPIKTRA, Verastem, Inc.) for adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) after at least two prior therapies. In... Continue Reading

FDA Approves Venetoclax for Chronic and Small Lymphocytic Leukemia/Lymphoma With or Without 17 p Deletion, (June 25, 2018)

The Food and Drug Administration granted regular approval to Venclexta (venetoclax) for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), with or without 17p deletion, who have received at least one prior therapy. Approval... Continue Reading

Venclexta Significantly Reduces Cancer Progression in Chronic Lymphocytic Leukemia (March 22, 2018)

CancerConnect News: Venclexta (venetoclax) plus Rituxan (rituximab) significantly reduces the risk of cancer progression or death at two years, compared with Treanda (bendustamine) plus Rituxan in the treatment of chronic lymphocytic leukemia that has... Continue Reading

Duvelisib; Promising New Treatment Option for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (September 11, 2017)

Results of the Phase 3 DUO study evaluating duvelisib in patients with relapsed or refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) have been reported and appear very promising.  Although the treatment of CLL/SLL has advanced... Continue Reading

Personalized Cell Therapy Combined with Imbruvica Achieves Complete Remission in High Percentage of Chronic Lymphocytic Leukemia Patients (June 5, 2017)

Combining the kinase inhibitor Imbruvica (ibrutinib) with an investigational personalized cellular therapy known as CTL119 can lead to complete remission in patients with high-risk chronic lymphocytic leukemia (CLL), according to new research from the Perelman... Continue Reading

More Chronic Lymphocytic Leukemia

Chronic Myeloid Leukemia

Flumatinib Shows Promise in Chronic-Phase Chronic Myeloid Leukemia (September 3, 2019)

Flumatinib may be more effective than Gleevec (imatinib) for initial treatment of chronic phase-chronic myeloid leukemia (CML-CP) according to study results presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. Chronic... Continue Reading

FDA Grants Accelerated Approval to Bosulif for Treatment of Newly-Diagnosed Chronic Myelogenous Leukemia (January 14, 2018)

CancerConnect News: On December 19, 2017, the Food and Drug Administration granted accelerated approval to bosutinib Bosulif (bosutinib) for treatment of patients with newly-diagnosed chronic phase (CP) Philadelphia chromosome positive (Ph+) chronic myelogenous... Continue Reading

Sprycel Effective for Treatment of Pediatric Chronic Myeloid Leukemia (June 14, 2017)

In 2002, the FDA approved the drug Gleevec (imatinib) as a first-line therapy for adults with chronic myeloid leukemia (CML) caused by the fusion gene BCR-ABL, known as the Philadelphia chromosome. The approval dramatically extended the lives of patients... Continue Reading

Have a Question about Chronic Myeloid Leukemia? Join us on May 25th! (May 2, 2017)

CancerConnect Presents: Ask the Expert with Dana-Farber Cancer Institute’s Dr. Luskin CancerConnect announces the opportunity to engage with leukemia expert, Marlise Luskin, MD, MSCE. On May 25th, 2017, Dr. Luskin will answer your pre-submitted questions... Continue Reading

FDA Grants Iclusig® Expanded Approval for CML (December 14, 2016)

The United States Food and Drug Administration (FDA) has granted Iclusig® (ponatinib) approval to treat all phases of chronic myeloid leukemia (CML) in adults, as well as Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ALL) who are... Continue Reading

More Chronic Myeloid Leukemia

Hairy Cell Leukemia

Zelboraf® Appears Active in Hairy Cell Leukemia That Has Progressed After Other Treatment (October 7, 2015)

The medication Zelboraf® (vemurafenib) appears active in the treatment of hairy cell leukemia (HCL) that had progressed after previous therapy. These findings were published in New England Journal of Medicine. Hairy cell leukemia is a rare type of leukemia,... Continue Reading

Zelboraf® Active in Hairy Cell Leukemia (September 24, 2015)

The targeted agent, Zelboraf® (vemurafenib), which is approved for the treatment of melanoma, provided high anti-cancer activity among patients with hairy-cell leukemia that had stopped responding to prior therapies. These results were recently published... Continue Reading

Many Patients with “Chemo Brain” Recover within Five Years (May 23, 2011)

A study of “chemo brain”—the foggy thinking and forgetfulness that patients may experience after chemotherapy—suggests that the condition improves substantially over time for a majority of patients. For some patients, however, symptoms may persist... Continue Reading

More Hairy Cell Leukemia

Screening/Prevention Leukemia

Exposure to Some Inflammatory Bowel Disease Drugs May Increase Leukemia Risk (August 8, 2014)

Thiopurines are an established treatment for inflammatory bowel disease (IBD) patients.  They are used to reduce inflammation and provide symptom relief.  Thiopurine immunosuppressive drugs have now been reported to increase the risk of acute myelod... Continue Reading

Link Between Allergies and Blood Cancers in Women (January 1, 2014)

Researchers hare found a link between airborne allergies and the risk of blood cancers in women, according to the results of a study published in the American Journal of Hematology. Cancer research has increasingly become focused on the immune system... Continue Reading

Childhood CT Scans Linked to Leukemia and Brain Cancer Later in Life (June 20, 2012)

Children and young adults who undergo multiple computed tomography (CT) scans have an increased risk of leukemia and brain tumors in the decade following their first scan, according to the results of a study published in The Lancet. CT scans are a common... Continue Reading

Aspirin Continues to Look Promising for Cancer Prevention (March 26, 2012)

A combined analysis of 51 randomized trials found that daily aspirin use reduces the risk of new cancer diagnoses as well as the risk of cancer death. These results were published in The Lancet. A growing body of evidence suggests that aspirin may reduce... Continue Reading

Greater Cancer Risk Among Taller Women (July 28, 2011)

Taller women may have an increased risk of developing certain cancers. Overall, cancer risk increases by 16% for every 4-inch increase in height. These findings were recently reported in Lancet Oncology. Greater insight into height and cancer risk may... Continue Reading

More Screening/Prevention Leukemia